{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:56:11Z","timestamp":1774526171969,"version":"3.50.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01769-4","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:52:27Z","timestamp":1774522347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["De-Escalation Strategies in Nasopharyngeal Carcinoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Yulu","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caineng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1769_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong KCW, Hui EP, Lo K-W, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18:679\u201395. https:\/\/doi.org\/10.1038\/s41571-021-00524-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"1769_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"Y-P Chen","year":"2021","unstructured":"Chen Y-P, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. JCO. 2021;39:840\u201359. https:\/\/doi.org\/10.1200\/JCO.20.03237.","journal-title":"JCO"},{"key":"1769_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ijrobp.2023.06.001","volume":"117","author":"L Xiang","year":"2023","unstructured":"Xiang L, Rong J-F, Xin-Chen null, Li X-Y, Zheng Y, Ren P-R, et al. Reducing target volumes of intensity modulated radiation therapy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a prospective, multicenter, randomized trial. Int J Radiat Oncol Biol Phys. 2023;117:914\u201324. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.001.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1769_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3322\/caac.21881","volume":"75","author":"L Tang","year":"2025","unstructured":"Tang L, Chen L, Xu G, Zhang N, Huang C, Li W, et al. Reduced-volume radiotherapy versus conventional\u2010volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: an open\u2010label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin. 2025;75:203\u201315. https:\/\/doi.org\/10.3322\/caac.21881.","journal-title":"CA Cancer J Clin"},{"key":"1769_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijrobp.2025.05.019","volume":"123","author":"S-J Lin","year":"2025","unstructured":"Lin S-J, Guo Q-J, Liu Q, Ng W-T, Ahn YC, AlHussain H, et al. International consensus guideline on delineation of the clinical target volumes at different dose levels for nasopharyngeal carcinoma (2024 version). Int J Radiation Oncology*Biology*Physics. 2025;123:415\u201331. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.019.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(19)30956-0.","journal-title":"Lancet"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"113336","DOI":"10.1016\/j.ejca.2023.113336","volume":"194","author":"S-S Guo","year":"2023","unstructured":"Guo S-S, Yang J-H, Sun X-S, Liu L-Z, Yang Z-C, Liu L-T, et al. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial. Eur J Cancer. 2023;194:113336. https:\/\/doi.org\/10.1016\/j.ejca.2023.113336.","journal-title":"Eur J Cancer"},{"key":"1769_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109860","volume":"188","author":"X Ding","year":"2023","unstructured":"Ding X, Cui X, Cui X, Wang S. Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: a meta-analysis. Radiother Oncol. 2023;188:109860. https:\/\/doi.org\/10.1016\/j.radonc.2023.109860.","journal-title":"Radiother Oncol"},{"key":"1769_CR10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/cncr.24049","volume":"115","author":"L Tang","year":"2009","unstructured":"Tang L, Mao Y, Liu L, Liang S, Chen Y, Sun Y, et al. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma. Cancer. 2009;115:680\u20138. https:\/\/doi.org\/10.1002\/cncr.24049.","journal-title":"Cancer"},{"issue":"200005","key":"1769_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/(SICI)1097-0347","volume":"22","author":"AD King","year":"2000","unstructured":"King AD, Ahuja AT, Leung S, Lam WWM, Teo P, Chan Y, et al. Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease. Head Neck. 2000;22(200005):275\u201381. https:\/\/doi.org\/10.1002\/(SICI)1097-0347. )22:3%253C275::AID-HED10%253E3.0.CO;2-N.","journal-title":"Head Neck"},{"key":"1769_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-98","volume":"12","author":"FC Ho","year":"2012","unstructured":"Ho FC, Tham IW, Earnest A, Lee KM, Lu JJ. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC Cancer. 2012;12:98. https:\/\/doi.org\/10.1186\/1471-2407-12-98.","journal-title":"BMC Cancer"},{"key":"1769_CR13","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1002\/cncr.28201","volume":"119","author":"J Li","year":"2013","unstructured":"Li J, Yuan X, Zhang L, Tang Y, Liu L, Chen X, et al. A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node\u2010negative nasopharyngeal carcinoma. Cancer. 2013;119:3170\u20136. https:\/\/doi.org\/10.1002\/cncr.28201.","journal-title":"Cancer"},{"key":"1769_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1470-2045(22)00058-4","volume":"23","author":"L-L Tang","year":"2022","unstructured":"Tang L-L, Huang C-L, Zhang N, Jiang W, Wu Y-S, Huang SH, et al. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022;23:479\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00058-4.","journal-title":"Lancet Oncol"},{"key":"1769_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-018-1087-x","volume":"13","author":"C-L Huang","year":"2018","unstructured":"Huang C-L, Xu C, Zhang Y, Zhou G-Q, Mao Y-P, Liu Q, et al. Feasibility of ipsilateral lower neck sparing irradiation for unilateral or bilateral neck node-negative nasopharyngeal carcinoma: systemic review and meta-analysis of 2, 521 patients. Radiat Oncol. 2018;13:141. https:\/\/doi.org\/10.1186\/s13014-018-1087-x.","journal-title":"Radiat Oncol"},{"key":"1769_CR16","doi-asserted-by":"publisher","DOI":"10.21037\/cco-22-73","volume":"11","author":"SS Poh","year":"2022","unstructured":"Poh SS, Wee JTS. Commentary on \u201celective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial.\u201d Chin Clin Oncol. 2022;11:35. https:\/\/doi.org\/10.21037\/cco-22-73.","journal-title":"Chin Clin Oncol"},{"key":"1769_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.109447","volume":"179","author":"G-L Zhu","year":"2023","unstructured":"Zhu G-L, Zhang X-M, Yang K-B, Tang L-L, Ma J. Metastatic patterns of level II-V cervical lymph nodes assessed per vertebral levels in nasopharyngeal carcinoma. Radiother Oncol. 2023;179:109447. https:\/\/doi.org\/10.1016\/j.radonc.2022.109447.","journal-title":"Radiother Oncol"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-23-3274","volume":"30","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yan W, Hu C, Huang X, Wang K, Qu Y, et al. Optimizing cervical target volume in patients with nasopharyngeal cancer based on nodal drainage distance. Clin Cancer Res. 2024;30:1801\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3274.","journal-title":"Clin Cancer Res"},{"key":"1769_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.radonc.2022.11.005","volume":"177","author":"G Wang","year":"2022","unstructured":"Wang G, Huang C, Yang K, Guo R, Qiu Y, Li W, et al. Neck level ib-sparing versus level ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: a propensity score-matched cohort study. Radiother Oncol. 2022;177:205\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2022.11.005.","journal-title":"Radiother Oncol"},{"key":"1769_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.5732\/cjc.012.10095","volume":"31","author":"W-F Li","year":"2012","unstructured":"Li W-F, Sun Y, Chen M, Tang L-L, Liu L-Z, Mao Y-P, et al. Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. Chin J Cancer. 2012;31:579\u201387. https:\/\/doi.org\/10.5732\/cjc.012.10095.","journal-title":"Chin J Cancer"},{"key":"1769_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.radonc.2021.12.032","volume":"167","author":"Q Guo","year":"2022","unstructured":"Guo Q, Xiao N, Xu H, Zong J, Xiao Y, Lu T, et al. Level ib sparing intensity-modulated radiation therapy in selected nasopharyngeal carcinoma patients based on the international guideline. Radiother Oncol. 2022;167:239\u201343. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.032.","journal-title":"Radiother Oncol"},{"key":"1769_CR22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.oraloncology.2014.08.007","volume":"50","author":"XS Wang","year":"2014","unstructured":"Wang XS, Yan C, Hu CS, Ying HM, He XY, Zhou ZR, et al. Study of the medial group retropharyngeal node metastasis from nasopharyngeal carcinoma based on 3100 newly diagnosed cases. Oral Oncol. 2014;50:1109\u201313. https:\/\/doi.org\/10.1016\/j.oraloncology.2014.08.007.","journal-title":"Oral Oncol"},{"key":"1769_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072133","volume":"380","author":"Y-P Mao","year":"2023","unstructured":"Mao Y-P, Wang S-X, Gao T-S, Zhang N, Liang X-Y, Xie F-Y, et al. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023;380:e072133. https:\/\/doi.org\/10.1136\/bmj-2022-072133.","journal-title":"BMJ"},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/pro6.1219","volume":"8","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Chen X, Yuan T. Precision radiotherapy for nasopharyngeal carcinoma. Precis Radiat Oncol. 2024;8:37\u201341. https:\/\/doi.org\/10.1002\/pro6.1219.","journal-title":"Precis Radiat Oncol"},{"key":"1769_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107060","volume":"159","author":"I Yacoub","year":"2024","unstructured":"Yacoub I, Qian JY, Nashed K, Youssef M, Khalil M, Kallini D, et al. Radiation techniques and advancements in nasopharyngeal carcinoma. Oral Oncol. 2024;159:107060. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.107060.","journal-title":"Oral Oncol"},{"key":"1769_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.13205","volume":"4","author":"X Li","year":"2021","unstructured":"Li X, Kitpanit S, Lee A, Mah D, Sine K, Sherman EJ, et al. Toxicity profiles and survival outcomes among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated proton therapy vs intensity-modulated radiation therapy. JAMA Netw Open. 2021;4:e2113205. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.13205.","journal-title":"JAMA Netw Open"},{"key":"1769_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/cancers14010225","volume":"14","author":"P-W Wu","year":"2022","unstructured":"Wu P-W, Huang C-C, Lee Y-S, Chou Y-C, Fan K-H, Lin C-Y, et al. Post-Irradiation Sinus Mucosa Disease in Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Proton TherapyPost-Irradiation Sinus Mucosa Disease in Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Proton Therapy. Cancers (Basel). 2022;14:225. https:\/\/doi.org\/10.3390\/cancers14010225.","journal-title":"Cancers (Basel)"},{"key":"1769_CR28","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.3390\/cancers13143555","volume":"13","author":"Y-C Chou","year":"2021","unstructured":"Chou Y-C, Fan K-H, Lin C-Y, Hung T-M, Huang B-S, Chang K-P, et al. Intensity Modulated Proton Beam Therapy versus Volumetric Modulated Arc Therapy for Patients with Nasopharyngeal Cancer: A Propensity Score-Matched Study. Cancers (Basel). 2021;13:3555. https:\/\/doi.org\/10.3390\/cancers13143555.","journal-title":"Cancers (Basel)"},{"key":"1769_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110648","volume":"202","author":"C-N Wu","year":"2025","unstructured":"Wu C-N, Wang J-D, Chen W-C, Lin C-Y, Chiu T-J, Yang Y-H, et al. Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: a long-term, multicenter cohort study. Radiother Oncol. 2025;202:110648. https:\/\/doi.org\/10.1016\/j.radonc.2024.110648.","journal-title":"Radiother Oncol"},{"key":"1769_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70003","volume":"4","author":"A Zhang","year":"2025","unstructured":"Zhang A, Fan L, Liu Q, Zuo X, Zhu J. Immunological effects of proton radiotherapy: new opportunities and challenges in cancer therapy. Cancer Innov. 2025;4:e70003. https:\/\/doi.org\/10.1002\/cai2.70003.","journal-title":"Cancer Innov"},{"key":"1769_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","volume":"99","author":"R Davuluri","year":"2017","unstructured":"Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2017;99:128\u201335. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.05.037.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1769_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11912-025-01673-3","volume":"27","author":"K Pazdro-Zastawny","year":"2025","unstructured":"Pazdro-Zastawny K, Krajewska J, Zastawny M, Dorobisz K. Carbon ion radiotherapy in the head and neck cancers treatment and its potential role in personalized treatment approach- a review of the current knowledge. Curr Oncol Rep. 2025;27:657\u201368. https:\/\/doi.org\/10.1007\/s11912-025-01673-3.","journal-title":"Curr Oncol Rep"},{"key":"1769_CR33","doi-asserted-by":"publisher","first-page":"653050","DOI":"10.3389\/fonc.2021.653050","volume":"11","author":"J Hu","year":"2021","unstructured":"Hu J, Huang Q, Gao J, Hu W, Yang J, Guan X, et al. Mixed Photon and Carbon-Ion Beam Radiotherapy in the Management of Non-Metastatic Nasopharyngeal Carcinoma. Front Oncol. 2021;11:653050. https:\/\/doi.org\/10.3389\/fonc.2021.653050.","journal-title":"Front Oncol"},{"key":"1769_CR34","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/hed.27771","volume":"46","author":"Y Li","year":"2024","unstructured":"Li Y, Guan X, Xing X, Hu C. Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT\u2009+\u2009carbon-ion radiotherapy: a propensity score-matched analysis. Head Neck. 2024;46:1766\u201376. https:\/\/doi.org\/10.1002\/hed.27771.","journal-title":"Head Neck"},{"key":"1769_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.clon.2011.11.010","volume":"24","author":"F Han","year":"2012","unstructured":"Han F, Zhao C, Huang S-M, Lu L-X, Huang Y, Deng X-W, et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol. 2012;24:569\u201376. https:\/\/doi.org\/10.1016\/j.clon.2011.11.010.","journal-title":"Clin Oncol"},{"key":"1769_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep32883","volume":"6","author":"L Kong","year":"2016","unstructured":"Kong L, Wang L, Shen C, Hu C, Wang L, Lu JJ. Salvage intensity-modulated radiation therapy (IMRT) for locally recurrent nasopharyngeal cancer after definitive IMRT: a novel scenario of the modern era. Sci Rep. 2016;6:32883. https:\/\/doi.org\/10.1038\/srep32883.","journal-title":"Sci Rep"},{"key":"1769_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5055-5","volume":"18","author":"F Kong","year":"2018","unstructured":"Kong F, Zhou J, Du C, He X, Kong L, Hu C, et al. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. BMC Cancer. 2018;18:1139. https:\/\/doi.org\/10.1186\/s12885-018-5055-5.","journal-title":"BMC Cancer"},{"key":"1769_CR38","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1002\/cncr.33197","volume":"126","author":"J Hu","year":"2020","unstructured":"Hu J, Huang Q, Gao J, Guan X, Hu W, Yang J, et al. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer. 2020;126:5173\u201383. https:\/\/doi.org\/10.1002\/cncr.33197.","journal-title":"Cancer"},{"key":"1769_CR39","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3389\/fonc.2020.01314","volume":"10","author":"X Huang","year":"2020","unstructured":"Huang X, Chen X, Zhao C, Wang J, Wang K, Wang L, et al. Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage II nasopharyngeal carcinoma: A phase 2 multicenter clinical trial. Front Oncol. 2020;10:1314. https:\/\/doi.org\/10.3389\/fonc.2020.01314.","journal-title":"Front Oncol"},{"key":"1769_CR40","doi-asserted-by":"publisher","first-page":"17378","DOI":"10.1038\/srep17378","volume":"5","author":"F Zhang","year":"2015","unstructured":"Zhang F, Zhang Y, Li W-F, Liu X, Guo R, Sun Y, et al. Efficacy of Concurrent Chemotherapy for Intermediate Risk NPC in the Intensity-Modulated Radiotherapy Era: a Propensity-Matched Analysis. Sci Rep. 2015;5:17378. https:\/\/doi.org\/10.1038\/srep17378.","journal-title":"Sci Rep"},{"key":"1769_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194733","volume":"13","author":"F Liu","year":"2018","unstructured":"Liu F, Jin T, Liu L, Xiang Z, Yan R, Yang H, et al. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a systematic review and meta-analysis. PLoS One. 2018;13:e0194733. https:\/\/doi.org\/10.1371\/journal.pone.0194733.","journal-title":"PLoS One"},{"key":"1769_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.7150\/jca.17317","volume":"8","author":"C Xu","year":"2017","unstructured":"Xu C, Zhang L-H, Chen Y-P, Liu X, Zhou G-Q, Lin A-H, et al. Chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients. J Cancer. 2017;8:287\u201397. https:\/\/doi.org\/10.7150\/jca.17317.","journal-title":"J Cancer"},{"key":"1769_CR43","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.currproblcancer.2018.03.004","volume":"42","author":"S Wang","year":"2018","unstructured":"Wang S, Li S, Shen L. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: a meta-analysis of the published literature. Curr Probl Cancer. 2018;42:302\u201318. https:\/\/doi.org\/10.1016\/j.currproblcancer.2018.03.004.","journal-title":"Curr Probl Cancer"},{"key":"1769_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jama.2022.13997","volume":"328","author":"L-L Tang","year":"2022","unstructured":"Tang L-L, Guo R, Zhang N, Deng B, Chen L, Cheng Z-B, et al. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022;328:728. https:\/\/doi.org\/10.1001\/jama.2022.13997.","journal-title":"JAMA"},{"key":"1769_CR45","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaoncol.2023.6552","volume":"10","author":"J Dai","year":"2024","unstructured":"Dai J, Zhang B, Su Y, Pan Y, Ye Z, Cai R, et al. Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: A randomized clinical trial. JAMA Oncol. 2024;10:456. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6552.","journal-title":"JAMA Oncol"},{"key":"1769_CR46","unstructured":"Huang P-Y, Zou X, Liu Y-P, Wang Z-M, Liu Y-L, Yu T et al. Induction versus concurrent chemotherapy for advanced nasopharyngeal carcinoma. 2025."},{"key":"1769_CR47","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamaoncol.2025.2191","volume":"11","author":"F Xue","year":"2025","unstructured":"Xue F, Ou D, Xie C, Lin S, Li J, Chen X, et al. Sequential vs induction plus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A randomized clinical trial. JAMA Oncol. 2025;11:1011. https:\/\/doi.org\/10.1001\/jamaoncol.2025.2191.","journal-title":"JAMA Oncol"},{"key":"1769_CR48","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.1200\/JCO.2004.00.7542","volume":"23","author":"AWM Lee","year":"2005","unstructured":"Lee AWM, Lau WH, Tung SY, Chua DTT, Chappell R, Xu L, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the hong kong nasopharyngeal cancer study group. JCO. 2005;23:6966\u201375. https:\/\/doi.org\/10.1200\/JCO.2004.00.7542.","journal-title":"JCO"},{"key":"1769_CR49","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ejca.2010.10.026","volume":"47","author":"AWM Lee","year":"2011","unstructured":"Lee AWM, Tung SY, Ngan RKC, Chappell R, Chua DTT, Lu TX, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer. 2011;47:656\u201366. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.026.","journal-title":"Eur J Cancer"},{"key":"1769_CR50","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","volume":"23","author":"J Wee","year":"2005","unstructured":"Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.16.790.","journal-title":"J Clin Oncol"},{"key":"1769_CR51","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1634\/theoncologist.2016-0105","volume":"21","author":"H Peng","year":"2016","unstructured":"Peng H, Chen L, Zhang Y, Li W-F, Mao Y-P, Zhang F, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a prospective phase III clinical trial. Oncologist. 2016;21:1369\u201376. https:\/\/doi.org\/10.1634\/theoncologist.2016-0105.","journal-title":"Oncologist"},{"key":"1769_CR52","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1200\/JCO.22.00099","volume":"40","author":"W-T Ng","year":"2022","unstructured":"Ng W-T, Chua MLK, Lee AWM. Identifying patients with low-risk locoregionally advanced nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA for chemotherapy deintensification: quo vadis? J Clin Oncol. 2022;40:1135\u20138. https:\/\/doi.org\/10.1200\/JCO.22.00099.","journal-title":"J Clin Oncol"},{"key":"1769_CR53","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JCO.21.01467","volume":"40","author":"X-Y Li","year":"2022","unstructured":"Li X-Y, Luo D-H, Guo L, Mo H-Y, Sun R, Guo S-S, et al. Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial. J Clin Oncol. 2022;40:1163\u201373. https:\/\/doi.org\/10.1200\/JCO.21.01467.","journal-title":"J Clin Oncol"},{"key":"1769_CR54","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/cas.13474","volume":"109","author":"J-W Lv","year":"2018","unstructured":"Lv J-W, Qi Z-Y, Zhou G-Q, He X-J, Chen Y-P, Mao Y-P, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. Cancer Sci. 2018;109:751\u201363. https:\/\/doi.org\/10.1111\/cas.13474.","journal-title":"Cancer Sci"},{"key":"1769_CR55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/cam4.4477","volume":"11","author":"Y-T Jiang","year":"2022","unstructured":"Jiang Y-T, Chen K-H, Yang J, Liang Z-G, Li L, Qu S, et al. Efficiency of high cumulative cisplatin dose in high- and low-risk patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Med. 2022;11:715\u201327. https:\/\/doi.org\/10.1002\/cam4.4477.","journal-title":"Cancer Med"},{"key":"1769_CR56","doi-asserted-by":"publisher","first-page":"104675","DOI":"10.1016\/j.oraloncology.2020.104675","volume":"107","author":"D-W Wen","year":"2020","unstructured":"Wen D-W, Li Z-X, Chen F-P, Lin L, Peng B-Y, Kou J, et al. Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy. Oral Oncol. 2020;107:104675. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104675.","journal-title":"Oral Oncol"},{"key":"1769_CR57","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1158\/1078-0432.CCR-21-3375","volume":"28","author":"W-T Ng","year":"2022","unstructured":"Ng W-T, Choi C-W, But B, Ngan RKC, Tung S, Cheng AC, et al. Exploratory study of NPC-0501 trial: Optimal cisplatin dose of concurrent and induction\/adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Clin Cancer Res. 2022;28:2679\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3375.","journal-title":"Clin Cancer Res"},{"key":"1769_CR58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.radonc.2015.11.030","volume":"118","author":"JY Lee","year":"2016","unstructured":"Lee JY, Sun J-M, Oh DR, Lim SH, Goo J, Lee S-H, et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiother Oncol. 2016;118:244\u201350. https:\/\/doi.org\/10.1016\/j.radonc.2015.11.030.","journal-title":"Radiother Oncol"},{"key":"1769_CR59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7150\/jca.21357","volume":"9","author":"D-F Meng","year":"2018","unstructured":"Meng D-F, Sun R, Peng L-X, Huang Y-S, Yang Q, Luo D-H, et al. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer. 2018;9:92\u20139. https:\/\/doi.org\/10.7150\/jca.21357.","journal-title":"J Cancer"},{"key":"1769_CR60","doi-asserted-by":"publisher","unstructured":"Tao C-J, Lin L, Zhou G-Q, Tang L-L, Chen L, Mao Y-P, et al. Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma. PLoS One. 2014;9:e110765. https:\/\/doi.org\/10.1371\/journal.pone.0110765.","DOI":"10.1371\/journal.pone.0110765"},{"key":"1769_CR61","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.bjorl.2019.04.008","volume":"86","author":"M Gundog","year":"2020","unstructured":"Gundog M, Basaran H, Bozkurt O, Eroglu C. A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma. Braz J Otorhinolaryngol. 2020;86:676\u201386. https:\/\/doi.org\/10.1016\/j.bjorl.2019.04.008.","journal-title":"Braz J Otorhinolaryngol"},{"key":"1769_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5688-z","volume":"19","author":"K Wang","year":"2019","unstructured":"Wang K, Dong J, He S, Wang X, Jiang C, Hu P, et al. Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma. BMC Cancer. 2019;19:482. https:\/\/doi.org\/10.1186\/s12885-019-5688-z.","journal-title":"BMC Cancer"},{"key":"1769_CR63","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-20-4532","volume":"27","author":"W-X Xia","year":"2021","unstructured":"Xia W-X, Lv X, Liang H, Liu G-Y, Sun R, Zeng Q, et al. A randomized controlled trial comparing two different schedules for cisplatin treatment in patients with locoregionally advanced nasopharyngeal cancer. Clin Cancer Res. 2021;27:4186\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4532.","journal-title":"Clin Cancer Res"},{"key":"1769_CR64","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1186\/s12885-022-09712-z","volume":"22","author":"Z Li","year":"2022","unstructured":"Li Z, Li C, Yang D, Song J, Liu T, Zhou Z, et al. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis. BMC Cancer. 2022;22:616. https:\/\/doi.org\/10.1186\/s12885-022-09712-z.","journal-title":"BMC Cancer"},{"key":"1769_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1758-3284-3-30","volume":"3","author":"T Dechaphunkul","year":"2011","unstructured":"Dechaphunkul T, Pruegsanusak K, Sangthawan D, Sunpaweravong P. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5- fluorouracil in locally advanced nasopharyngeal carcinoma. Head Neck Oncol. 2011;3:30. https:\/\/doi.org\/10.1186\/1758-3284-3-30.","journal-title":"Head Neck Oncol"},{"key":"1769_CR66","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ejca.2007.03.022","volume":"43","author":"I Chitapanarux","year":"2007","unstructured":"Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Sumitsawan Y, Tharavichitkul E, Sukthomya V, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trial. Eur J Cancer. 2007;43:1399\u2013406. https:\/\/doi.org\/10.1016\/j.ejca.2007.03.022.","journal-title":"Eur J Cancer"},{"key":"1769_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2478\/raon-2014-0044","volume":"49","author":"A Songthong","year":"2015","unstructured":"Songthong A, Chakkabat C, Kannarunimit D, Lertbutsayanukul C. Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma. Radiol Oncol. 2015;49:155\u201362. https:\/\/doi.org\/10.2478\/raon-2014-0044.","journal-title":"Radiol Oncol"},{"key":"1769_CR68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","volume":"23","author":"AD Colevas","year":"2025","unstructured":"Colevas AD, Cmelak AJ, Pfister DG, Spencer S, Adkins D, Birkeland AC, et al. NCCN guidelines\u00ae insights: Head and neck cancers, version 2.2025: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2025;23:2\u201311. https:\/\/doi.org\/10.6004\/jnccn.2025.0007.","journal-title":"J Natl Compr Canc Netw"},{"key":"1769_CR69","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2018.0026","volume":"16","author":"AD Colevas","year":"2018","unstructured":"Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN guidelines insights: Head and neck cancers, version 1.2018. J Natl Compr Canc Netw. 2018;16:479\u201390. https:\/\/doi.org\/10.6004\/jnccn.2018.0026.","journal-title":"J Natl Compr Canc Netw"},{"key":"1769_CR70","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0016","author":"C Jj","year":"2022","unstructured":"Jj C, Ml G, E M, Dg SS. NCCN guidelines\u00ae insights: Head and neck cancers, version 1.2022. Journal of the National Comprehensive Cancer Network: JNCCN [Internet]. J Natl Compr Canc Netw. 2022. https:\/\/doi.org\/10.6004\/jnccn.2022.0016. [cited 2025 July 26];20.","journal-title":"J Natl Compr Canc Netw"},{"key":"1769_CR71","doi-asserted-by":"publisher","DOI":"10.7150\/jca.47090","author":"Z Zj","year":"2020","unstructured":"Zj Z, Hy T, Wz Q, Zy L, Rx Z, K L, et al. Clinical value of nedaplatin-based chemotherapy combined with radiotherapy for locoregional advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. J Cancer. 2020. https:\/\/doi.org\/10.7150\/jca.47090.","journal-title":"J Cancer"},{"key":"1769_CR72","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.7150\/jca.27198","volume":"9","author":"T Liu","year":"2018","unstructured":"Liu T, Sun Q, Chen J, Li B, Qin W, Wang F, et al. Neoadjuvant chemotherapy with fluorouracil plus nedaplatin or cisplatin for locally advanced nasopharyngeal carcinoma: A retrospective study. J Cancer. 2018;9:3676\u201382. https:\/\/doi.org\/10.7150\/jca.27198.","journal-title":"J Cancer"},{"key":"1769_CR73","doi-asserted-by":"publisher","unstructured":"C D, N Z, S J, H Z, J M, W Z, et al. Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients. Sci Rep [Internet]. 2022 [cited 2025 July 18];12. https:\/\/doi.org\/10.1038\/s41598-022-16216-0","DOI":"10.1038\/s41598-022-16216-0"},{"key":"1769_CR74","doi-asserted-by":"publisher","first-page":"e2138470","DOI":"10.1001\/jamanetworkopen.2021.38470","volume":"4","author":"Q-N Tang","year":"2021","unstructured":"Tang Q-N, Liu L-T, Qi B, Guo S-S, Luo D-H, Sun R, et al. Effect of concurrent chemoradiotherapy with nedaplatin vs cisplatin on the long-term outcomes of survival and toxic effects among patients with stage II to IVB nasopharyngeal carcinoma: A 5-year follow-up secondary analysis of a randomized clinical trial. JAMA Netw Open. 2021;4:e2138470. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.38470.","journal-title":"JAMA Netw Open"},{"key":"1769_CR75","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","volume":"22","author":"X Lv","year":"2021","unstructured":"Lv X, Cao X, Xia W-X, Liu K-Y, Qiang M-Y, Guo L, et al. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: An open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:716\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(21)00075-9.","journal-title":"Lancet Oncol"},{"key":"1769_CR76","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","volume":"19","author":"L-Q Tang","year":"2018","unstructured":"Tang L-Q, Chen D-P, Guo L, Mo H-Y, Huang Y, Guo S-S, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: An open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19:461\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30104-9.","journal-title":"Lancet Oncol"},{"key":"1769_CR77","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/13543784.2016.1181747","volume":"25","author":"H Iqbal","year":"2016","unstructured":"Iqbal H, Pan Q. Capecitabine for treating head and neck cancer. Expert Opin Investig Drugs. 2016;25:851\u20139. https:\/\/doi.org\/10.1080\/13543784.2016.1181747.","journal-title":"Expert Opin Investig Drugs"},{"key":"1769_CR78","doi-asserted-by":"publisher","first-page":"107119","DOI":"10.1016\/j.oraloncology.2024.107119","volume":"160","author":"C Yan","year":"2025","unstructured":"Yan C, Wang R, Zhang C, Lin G, Du Y, Chen M, et al. Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF. Oral Oncol. 2025;160:107119. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.107119.","journal-title":"Oral Oncol"},{"key":"1769_CR79","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoncol.2022.0122","volume":"8","author":"W-Z Li","year":"2022","unstructured":"Li W-Z, Lv X, Hu D, Lv S-H, Liu G-Y, Liang H, et al. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022;8:706\u201314. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0122.","journal-title":"JAMA Oncol"},{"key":"1769_CR80","doi-asserted-by":"publisher","first-page":"101625","DOI":"10.1016\/j.eclinm.2022.101625","volume":"53","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang C, He S, Bai L, Kong F, Wang S, et al. Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial. eClinicalMedicine. 2022;53:101625. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101625.","journal-title":"eClinicalMedicine"},{"key":"1769_CR81","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil\u2013based paclitaxel in women with breast cancer. JCO. 2005;23:7794\u2013803. https:\/\/doi.org\/10.1200\/JCO.2005.04.937.","journal-title":"JCO"},{"key":"1769_CR82","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.07.001","volume":"72","author":"D Adkins","year":"2017","unstructured":"Adkins D, Ley J, Oppelt P, Wildes TM, Gay HA, Daly M, et al. nab-paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral Oncol. 2017;72:26\u201331. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.07.001.","journal-title":"Oral Oncol"},{"key":"1769_CR83","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab -paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non\u2013small-cell lung cancer: Final results of a phase III trial. JCO. 2012;30:2055\u201362. https:\/\/doi.org\/10.1200\/JCO.2011.39.5848.","journal-title":"JCO"},{"key":"1769_CR84","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/cam4.382","volume":"4","author":"A Schell","year":"2015","unstructured":"Schell A, Ley J, Wu N, Trinkaus K, Wildes TM, Michel L, et al. Nab-paclitaxel\u2010based compared to docetaxel\u2010based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. Cancer Med. 2015;4:481\u20139. https:\/\/doi.org\/10.1002\/cam4.382.","journal-title":"Cancer Med"},{"key":"1769_CR85","doi-asserted-by":"publisher","first-page":"110051","DOI":"10.1016\/j.radonc.2023.110051","volume":"191","author":"M-J Yu-Chen, Luo","year":"2024","unstructured":"Yu-Chen, Luo M-J, Liu R-P, Jin J, Deng S-W, Tang L-Q, et al. Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma. Radiother Oncol. 2024;191:110051. https:\/\/doi.org\/10.1016\/j.radonc.2023.110051.","journal-title":"Radiother Oncol"},{"key":"1769_CR86","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","volume":"24","author":"Y-P Chen","year":"2018","unstructured":"Chen Y-P, Tang L-L, Yang Q, Poh S-S, Hui EP, Chan ATC, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: Individual patient data pooled analysis of four randomized trials. Clin Cancer Res. 2018;24:1824\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2656.","journal-title":"Clin Cancer Res"},{"key":"1769_CR87","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu G-Q, Zhang N, Zhu X-D, Yang K-Y, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381:1124\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1905287.","journal-title":"N Engl J Med"},{"key":"1769_CR88","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li W-F, Chen N-Y, Zhang N, Hu G-Q, Xie F-Y, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(16)30410-7.","journal-title":"Lancet Oncol"},{"key":"1769_CR89","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","volume":"145","author":"W Li","year":"2019","unstructured":"Li W, Chen N, Zhang N, Hu G, Xie F, Sun Y, et al. Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145:295\u2013305. https:\/\/doi.org\/10.1002\/ijc.32099.","journal-title":"Int J Cancer"},{"key":"1769_CR90","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","volume":"8","author":"J Miao","year":"2022","unstructured":"Miao J, Wang L, Tan SH, Li J, Yi J, Ong EHW, et al. Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A randomized clinical trial. JAMA Oncol. 2022;8:1776. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4656.","journal-title":"JAMA Oncol"},{"key":"1769_CR91","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"Y-P Chen","year":"2021","unstructured":"Chen Y-P, Liu X, Zhou Q, Yang K-Y, Jin F, Zhu X-D, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398:303\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(21)01123-5.","journal-title":"Lancet"},{"key":"1769_CR92","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13:659\u201373. https:\/\/doi.org\/10.1038\/nrclinonc.2016.64.","journal-title":"Nat Rev Clin Oncol"},{"key":"1769_CR93","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","volume":"7","author":"E Pasquier","year":"2010","unstructured":"Pasquier E, Kavallaris M, Andr\u00e9 N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455\u201365. https:\/\/doi.org\/10.1038\/nrclinonc.2010.82.","journal-title":"Nat Rev Clin Oncol"},{"key":"1769_CR94","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S1470-2045(13)70056-1","volume":"14","author":"N Andr\u00e9","year":"2013","unstructured":"Andr\u00e9 N, Banavali S, Snihur Y, Pasquier E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 2013;14:e239-48. https:\/\/doi.org\/10.1016\/S1470-2045(13)70056-1.","journal-title":"Lancet Oncol"},{"key":"1769_CR95","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2025.1132","volume":"333","author":"Y-L Liang","year":"2025","unstructured":"Liang Y-L, Liu X, Shen L-F, Hu G-Y, Zou G-R, Zhang N, et al. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial. JAMA. 2025;333:1589\u201398. https:\/\/doi.org\/10.1001\/jama.2025.1132.","journal-title":"JAMA"},{"key":"1769_CR96","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yang K-Y, Zhang N, Jin F, Zou G-R, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403:2720\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(24)00594-4.","journal-title":"Lancet"},{"key":"1769_CR97","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/jama.2025.13205","volume":"334","author":"C Xu","year":"2025","unstructured":"The DIAMOND Study Group, Xu C, Liang X-Y, Huang X-Q, Jin F, Yang K-Y, et al. Toripalimab combination therapy without concurrent cisplatin for nasopharyngeal carcinoma: The DIAMOND randomized clinical trial. JAMA. 2025;334:973. https:\/\/doi.org\/10.1001\/jama.2025.13205.","journal-title":"JAMA"},{"key":"1769_CR98","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.7150\/jca.46429","volume":"11","author":"L Chen","year":"2020","unstructured":"Chen L, Lin G, Chen K, Liang R, Wan F, Zhang C, et al. VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma. J Cancer. 2020;11:7291\u2013301. https:\/\/doi.org\/10.7150\/jca.46429.","journal-title":"J Cancer"},{"key":"1769_CR99","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/cncr.33626","volume":"127","author":"X Ruan","year":"2021","unstructured":"Ruan X, Liang J-H, Pan Y, Cai R, Zhang RJ, He Z, et al. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study. Cancer. 2021;127:3163\u201371. https:\/\/doi.org\/10.1002\/cncr.33626.","journal-title":"Cancer"},{"key":"1769_CR100","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12916-023-03140-x","volume":"21","author":"Y Fang","year":"2023","unstructured":"Fang Y, Su N, Zou Q, Cao Y, Xia Y, Tang L, et al. Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm, phase 2 clinical trial. BMC Med. 2023;21:423. https:\/\/doi.org\/10.1186\/s12916-023-03140-x.","journal-title":"BMC Med"},{"key":"1769_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2019.06.007","volume":"44","author":"Y Li","year":"2020","unstructured":"Li Y, Tian Y, Jin F, Wu W, Long J, Ouyang J, et al. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: long-term outcomes update. Curr Probl Cancer. 2020;44:100492. https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.06.007.","journal-title":"Curr Probl Cancer"},{"key":"1769_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-022-02104-4","volume":"17","author":"Y Yin","year":"2022","unstructured":"Yin Y, Zhou Z, Li Z, Shen M, Qin Y, Yang C, et al. Efficacy of concurrent chemoradiotherapy plus endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol. 2022;17:135. https:\/\/doi.org\/10.1186\/s13014-022-02104-4.","journal-title":"Radiat Oncol"},{"key":"1769_CR103","unstructured":"Xu L, Li D, Ji J, Chen Z, Tang X, Chen D et al. Recombinant human endostatin injection (endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical study."},{"key":"1769_CR104","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05762-x","volume":"150","author":"J-M Song","year":"2024","unstructured":"Song J-M, Mo N, Lv Y-Q, Huang L-L, Wen Y-J, Liu T, et al. Effects of concurrent chemoradiotherapy with or without endostar on the regression of retropharyngeal lymph node and prognosis of patients with locally advanced nasopharyngeal carcinoma: a retrospective study. J Cancer Res Clin Oncol. 2024;150:232. https:\/\/doi.org\/10.1007\/s00432-024-05762-x.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1769_CR105","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1200\/JCO.2024.42.16_suppl.6002","volume":"42","author":"M Kang","year":"2024","unstructured":"Kang M, Ma D, Gao J, Wang F, Yu B, Lu Y, et al. Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial. JCO. 2024;42:6002\u20136002. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.6002.","journal-title":"JCO"},{"key":"1769_CR106","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/annonc\/mdz020","volume":"30","author":"C Zhao","year":"2019","unstructured":"Zhao C, Miao J, Shen G, Li J, Shi M, Zhang N, et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. Ann Oncol. 2019;30:637\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdz020.","journal-title":"Ann Oncol"},{"key":"1769_CR107","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12916-025-04103-0","volume":"23","author":"Q Zou","year":"2025","unstructured":"Zou Q, Cao Y, Lai Y, Fang Y, Zhang Y, Liu P, et al. Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, phase 2 trial. BMC Med. 2025;23:264. https:\/\/doi.org\/10.1186\/s12916-025-04103-0.","journal-title":"BMC Med"},{"key":"1769_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11608-5","volume":"23","author":"Z Yang","year":"2023","unstructured":"Yang Z, Zuo Q, Liu R, Wu H, Xiong L, Jia J, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. BMC Cancer. 2023;23:1140. https:\/\/doi.org\/10.1186\/s12885-023-11608-5.","journal-title":"BMC Cancer"},{"key":"1769_CR109","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1200\/JCO.2022.40.16_suppl.6001","volume":"40","author":"Y Sun","year":"2022","unstructured":"Sun Y, Hu C, Lin Q, Gao L, Wang J, Zhu X, et al. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial. JCO. 2022;40:6001\u20136001. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.6001.","journal-title":"JCO"},{"key":"1769_CR110","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/cas.16213","volume":"115","author":"C Cao","year":"2024","unstructured":"Cao C, Fang Y, Jiang F, Jin Q, Jin T, Huang S, et al. Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma. Cancer Sci. 2024;115:2729\u201337. https:\/\/doi.org\/10.1111\/cas.16213.","journal-title":"Cancer Sci"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01769-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01769-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01769-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:52:30Z","timestamp":1774522350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01769-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01769-4","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}